{"id":"vct220-tablet","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PCSK9, VCT220 Tablet inhibits the degradation of LDL receptors, leading to increased clearance of LDL cholesterol from the bloodstream. This results in a reduction in LDL cholesterol levels, which can help to slow the progression of atherosclerotic cardiovascular disease.","oneSentence":"VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:21.235Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT07349381","phase":"PHASE1","title":"A Food-Effect Study of CX11 in Healthy Participants","status":"RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2026-03-04","conditions":"Obesity & Overweight, Type 2 Diabetes","enrollment":32},{"nctId":"NCT06939296","phase":"PHASE3","title":"A Research Study of VCT220 in Adult Chinese Participants With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2024-12-24","conditions":"Obesity, Overweight","enrollment":840},{"nctId":"NCT07360275","phase":"PHASE2","title":"A Study of VCT220 in Participants With Hypertension and Obesity or Overweight","status":"NOT_YET_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2026-03-01","conditions":"Hypertension","enrollment":160},{"nctId":"NCT07340320","phase":"PHASE2","title":"A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus","status":"NOT_YET_RECRUITING","sponsor":"Corxel Pharmaceuticals","startDate":"2026-02-05","conditions":"Type II Diabetes Mellitus","enrollment":240},{"nctId":"NCT06938529","phase":"PHASE1","title":"A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function","status":"COMPLETED","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-04-18","conditions":"Obesity, Overweight","enrollment":24},{"nctId":"NCT07011797","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corxel Pharmaceuticals","startDate":"2025-06-17","conditions":"Obesity","enrollment":250},{"nctId":"NCT06569355","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population","status":"COMPLETED","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2023-12-27","conditions":"Obesity, Overweight","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35895,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CX11"],"phase":"phase_3","status":"active","brandName":"VCT220 Tablet","genericName":"VCT220 Tablet","companyName":"Vincentage Pharma Co., Ltd","companyId":"vincentage-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}